BackgroundSengers syndrome is an autosomal recessive condition characterized by congenital cataract, hypertrophic cardiomyopathy, skeletal myopathy and lactic acidosis. Mutations in the acylglycerol kinase (AGK) gene have been recently described as the cause of Sengers syndrome in nine families.MethodsWe investigated the clinical and molecular features of Sengers syndrome in seven new families; five families with the severe and two with the milder form.ResultsSequence analysis of AGK revealed compound heterozygous or homozygous predicted loss-of-function mutations in all affected individuals. A total of eight different disease alleles were identified, of which six were novel, homozygous c.523_524delAT (p.Ile175Tyrfs*2), c.424-1G > A (splice site), c.409C > T (p.Arg137*) and c.877 + 3G > T (splice site), and compound heterozygous c.871C > T (p.Gln291*) and c.1035dup (p.Ile346Tyrfs*39). All patients displayed perinatal or early-onset cardiomyopathy and cataract, clinical features pathognomonic for Sengers syndrome. Other common findings included blood lactic acidosis and tachydyspnoea while nystagmus, eosinophilia and cervical meningocele were documented in only either one or two cases. Deficiency of the adenine nucleotide translocator was found in heart and skeletal muscle biopsies from two patients associated with respiratory chain complex I deficiency. In contrast to previous findings, mitochondrial DNA content was normal in both tissues.ConclusionWe compare our findings to those in 21 previously reported AGK mutation-positive Sengers patients, confirming that Sengers syndrome is a clinically recognisable disorder of mitochondrial energy metabolism.

This is the first report of determination of an NPHP1 deletion size using routine diagnostic methods. The results of this study expand the knowledge about the genotype-phenotype correlations in NPHP1, and have implications for genetic counseling and family planning advice for other affected families. This is the first molecular analysis of NPHP1 in an Iranian kindred.

References1 Imperial R, Helwig EB. Angiokeratoma. A clinicopathological study. Arch Dermatol 1967; 95:166-75. 2 Schiller PI, Itin PH. Angiokeratomas: an update. Dermatology 1996; 193:275-82. 3 Anderson W. A case of angiokeratoma. Br J Dermatol 1898; 10:113-17. 4 Holmes RC, Fensom AH, McKee P et al. Angiokeratoma corporis diffusum in a patient with normal enzyme activities. J Am Acad Dermatol 1984; 10:384-7. 5 Vargas-Díez E, Chabás A, Coll MJ et al. Angiokeratoma corporis diffusum in a Spanish patient with aspartylglucosaminuria. Br J Dermatol 2002; 147:760-4. 6 Kelly B, Kelly E. Angiokeratoma corporis diffusum in a patient with no recognizable enzyme abnormalities. Arch Dermatol 2006; 142:615-18. 7 Fleming C, Rennie A, Fallowfield M, McHenry PM. Cutaneous manifestations of fucosidosis. Br J Dermatol 1997; 136:594-7. 8 Zampetti A, Orteu CH, Antuzzi D et al. Angiokeratoma: decisionmaking aid for the diagnosis of Fabry disease. Br J Dermatol 2012; 166:712-20. 9 Smith BL, Chu P, Weinberg JM. Agiokeratomas of the vulva: possible association with radiotherapy. Skinmed 2004; 3:171-2. 10 Brown CA, Hall CL, Long JC et al. Circulating immune complexes in Hodgkin's disease. Am J Med 1978; 64:289-94.Funding sources: none.Conflicts of interest: none declared.

Tyrosinemia type I (HT1) is a genetic metabolic disorder characterized by progressive liver disease, kidney disease, and rickets. The disease is caused by mutations in the FAH gene that results in deficiency of fumarylacetoacetase, an enzyme that is involved in the tyrosine degradation pathway. We investigated the clinical characteristics and molecular cause of HT1 in an affected family from Iran. Molecular analysis identified a homozygous combined missense (c.G1009G>A, p.Gly337Ser) and aberrant splicing mutation removing the first 50 nucleotides of exon 12. This mutation was only described in HT1 patients from Scandinavian countries and this is the first report from another population. Although failure to thrive is one of the typical features in HT1, our proband, similar to the reported Scandinavian patients, had normal growth and development. The results of this study have applications in patient screening and genetic counselling.